公告称，本集团全科医疗服务产生的收益增长乃主要由于全科医疗服务病人就诊次数增加及每次就诊的 平均支出减少的抵销所致。 盈健医疗(01419)发布截至2025年12月31日止六个月(2026财年中期)的中期业绩，收益约为3.42亿港元， 较2025财年中期增加约2660万港元或8.4%;本公司拥有人应占溢利约为1830万港元，较2025财年中期约 1680万港元增加约150万港元或8.5%;每股基本盈利约为4.8港仙。 ...

公告称，本集团全科医疗服务产生的收益增长乃主要由于全科医疗服务病人就诊次数增加及每次就诊的 平均支出减少的抵销所致。 智通财经APP讯，盈健医疗(01419)发布截至2025年12月31日止六个月(2026财年中期)的中期业绩，收益 约为3.42亿港元，较2025财年中期增加约2660万港元或8.4%;本公司拥有人应占溢利约为1830万港元， 较2025财年中期约1680万港元增加约150万港元或8.5%;每股基本盈利约为4.8港仙。 ...

Core Viewpoint - Shantou City has been recognized for its healthcare capabilities with the inclusion of its General Medicine Department in the national clinical key specialty list, highlighting its leadership in medical services within the Chaoshan region [1] Group 1: Healthcare Development - The inclusion of Shantou City's General Medicine Department in the national clinical key specialty list signifies the city's growing influence as a provincial sub-center in healthcare services [1] - Shantou has established itself as a regional medical center, enhancing its position in the Shantou-Chaozhou-Jieyang urban agglomeration and providing advanced medical services to local residents [1][2] - The development of key specialties like oncology and general medicine strengthens the foundation of the provincial regional medical center, ensuring better healthcare access for the community [1] Group 2: Department Achievements - The General Medicine Department at Shantou City Central Hospital has a strong foundation, being one of the earliest and largest general medicine training bases in the region since its establishment in 2013 [2] - The department has developed an innovative "hospital-community-family" model for comprehensive healthcare management, facilitating seamless connections with community health service centers [2] - The department's focus on chronic disease management and preventive care has set a benchmark for improving grassroots healthcare services in the region [2] Group 3: Leadership and Research - The department is led by Wang Hao, a prominent figure in chronic disease research and a key talent in Guangdong's innovation plan, contributing significantly to national and provincial research projects [3] - Shantou City Central Hospital has achieved a breakthrough by having two national clinical key specialties, enhancing its reputation as a leading medical institution in the Chaoshan area [3] - The hospital aims to provide superior medical services to 15 million residents in Eastern Guangdong, aligning with the goals of provincial healthcare development [3]

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

Group 1 - The core stock price of Yingjian Medical (01419.HK) closed at HKD 1.110 on August 13, down 1.77% from the previous trading day, with an intraday high of HKD 1.160, marking a nearly one-year high [1] - The company experienced a net inflow of HKD 17.59 thousand on that day, with unspecified amounts flowing in and out [1] - Yingjian Medical Group Limited, established in 1997, is one of the largest medical groups in Hong Kong, listed on the Hong Kong Stock Exchange under stock code 1419 [1] Group 2 - The group operates under the brands "Human Health Integrated Medical Centre," "Human Health Medical Centre," and "Perfect Life," providing comprehensive primary healthcare services [1] - Yingjian Medical has over 60 medical centers across Hong Kong, Kowloon, the New Territories, and outlying islands, offering a wide range of services including prevention, health maintenance, diagnosis, and treatment [1] - The company aims to expand its network of medical centers and establish specialized medical service centers, adhering to its corporate culture of "benevolence" to ensure more citizens can access quality healthcare services [1]

Group 1 - The core viewpoint of the news highlights the performance of Yingjian Medical (盈健医疗) in the Hong Kong stock market, noting a significant increase in its stock price and a comparison of its financial metrics against industry averages [1] - As of July 23, the Hang Seng Index rose by 1.62%, while Yingjian Medical's stock price increased by 13.95%, closing at HKD 0.98 per share with a trading volume of 1.094 million shares [1] - Over the past month, Yingjian Medical has seen a cumulative increase of 6.17%, but it has underperformed compared to the Hang Seng Index, which has risen by 25.27% year-to-date [1] Group 2 - Financial data indicates that Yingjian Medical achieved total revenue of HKD 292 million for the year ending December 31, 2024, reflecting a year-on-year growth of 6.98%, while its net profit attributable to shareholders decreased by 16.03% to HKD 15.5778 million [1] - The company's gross profit margin stands at 47.09%, and its debt-to-asset ratio is 25.1% [1] - In terms of industry valuation, the average price-to-earnings (P/E) ratio for the healthcare equipment and services sector is -1.96x, with a median of 1.36x, while Yingjian Medical's P/E ratio is 15.56x, ranking 25th in the industry [1]